CG Oncology, Inc. (NASDAQ:CGON) Stock Now Rated “Moderate Buy” by Wall Street Analysts

CG Oncology, Inc. (NASDAQ:CGON) has been given a consensus recommendation of “Moderate Buy” by the eleven ratings firms that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and nine have assigned a buy rating to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $88.11.

CGON has been the subject of a number of research analyst reports. Wall Street Zen raised CG Oncology from a “strong sell” rating to a “sell” rating in a report on Saturday, November 7th. Wedbush boosted their price objective on shares of CG Oncology from $80.00 to $84.00 and gave the company an “outperform” rating in a research note on Friday, November 6th. HC Wainwright reissued a “buy” rating and issued a $100.00 price target on shares of CG Oncology in a report on Wednesday, July 29th. Royal Bank Of Canada dropped their price objective on CG Oncology from $81.00 to $79.00 and set an “outperform” rating on the stock in a report on Friday, August 7th. Finally, Guggenheim reduced their target price on CG Oncology from $90.00 to $89.00 and set a “buy” rating for the company in a report on Monday.

CG Oncology Price Performance

NASDAQ CGON opened at $72.61 on Thursday. CG Oncology has a 1 year low of $37.01 and a 1 year high of $80.97. The company has a market capitalization of $6.49 billion, a PE ratio of -26.31 and a beta of 0.35. The company has a fifty day moving average of $68.13 and a 200 day moving average of $66.36.

CG Oncology (NASDAQ:CGON) last posted its earnings results on Friday, November 6th. The company reported ($0.64) EPS for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.19. The firm had revenue of $1.60 million for the quarter, compared to analysts’ expectations of $0.55 million. CG Oncology had a negative return on equity of 24.58% and a negative net margin of 3,851.09%. Research analysts expect that CG Oncology will post -3.03 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Leonard E. Post sold 1,000 shares of the firm’s stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $62.06, for a total transaction of $62,060.00. Following the completion of the sale, the director owned 1,000 shares of the company’s stock, valued at approximately $62,060. This trade represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last quarter, insiders sold 3,000 shares of company stock worth $209,580. Insiders own 4.80% of the company’s stock.

Institutional Trading of CG Oncology

Hedge funds and other institutional investors have recently modified their holdings of the company. Fiduciary Financial Advisors acquired a new stake in shares of CG Oncology during the 2nd quarter valued at $28,000. NFSG Corp purchased a new stake in shares of CG Oncology during the first quarter worth $34,000. Manchester Capital Management LLC raised its holdings in shares of CG Oncology by 2,895.5% during the third quarter. Manchester Capital Management LLC now owns 659 shares of the company’s stock worth $47,000 after acquiring an additional 637 shares in the last quarter. Covestor Ltd boosted its position in CG Oncology by 72.6% during the third quarter. Covestor Ltd now owns 770 shares of the company’s stock valued at $55,000 after purchasing an additional 324 shares during the last quarter. Finally, Fifth Third Bancorp acquired a new stake in CG Oncology during the first quarter valued at $74,000. Institutional investors own 26.56% of the company’s stock.

Key CG Oncology News

These are some of the CGON news items that stood out recently:

• Positive Sentiment: CG Oncology’s third-quarter loss was narrower than analysts expected, and revenue exceeded estimates. HC Wainwright also maintained a Buy rating and a $100 price target, raising its FY2026 and Q4 2026 earnings forecasts. What CG Oncology’s Third Quarter Earnings Means For Shareholders
• Neutral Sentiment: A short-interest update reported zero shares sold short and a zero-day days-to-cover ratio, despite describing short interest as having increased. The figures do not indicate a meaningful short position.
• Negative Sentiment: HC Wainwright lowered its earnings forecasts for FY2027, FY2028 and FY2030, suggesting it expects a slower path to profitability farther out, although it kept its Buy rating and $100 target.

About CG Oncology

CG Oncology is a clinical-stage biotechnology company focused on developing treatments for bladder cancer. Based in Irvine, California, the company’s research centers on therapies delivered directly into the bladder. Its lead investigational therapy, cretostimogene grenadenorepvec (formerly CG0070), is an oncolytic immunotherapy being developed for non-muscle-invasive bladder cancer, including disease that has not responded to Bacillus Calmette-Guérin (BCG) treatment. The modified virus is designed to target cancer cells and stimulate an immune response.